Savara Raises $100 Million Following Lung Disease Treatment Breakthrough

1. Savara Raises $100 Million: Savara has raised $100 million in funding, which was fueled by the success of its experimental autoimmune pulmonary alveolar proteinosis (aPAP) treatment for lung disease.
2. Lung Disease Treatment Breakthrough: The company's shares rose about 7% on Friday following the announcement of the successful treatment.
3. European Commission Approval: The European Commission has approved Valneva's live-attenuated vaccine Ixchiq to prevent disease.
4. Pharma Industry News: The raise is significant in the context of recent pharma industry news, including AstraZeneca's $80 billion sales plan and FDA approvals for various drugs.